These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 19762092)

  • 1. Precaution, cyclooxygenase inhibition, and cardiovascular risk.
    Ritter JM; Harding I; Warren JB
    Trends Pharmacol Sci; 2009 Oct; 30(10):503-8. PubMed ID: 19762092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib and cardiovascular risks.
    Brophy JM
    Expert Opin Drug Saf; 2005 Nov; 4(6):1005-15. PubMed ID: 16255660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cardiovascular toxicity of selective COX-2-inhibitors and classical NSAIDs].
    Lange H; Eberhart L
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2007 Jul; 42(7):514-7. PubMed ID: 17661262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofecoxib was withdrawn in Australia?
    Barozzi N; Tett SE
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1184-91. PubMed ID: 17636557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The practice implications of cardiovascular risks in NSAIDs.
    Hainsworth T
    Nurs Times; 2005 Jun 28-Jul 4; 101(26):26-7. PubMed ID: 16010838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2 selective nonsteroidal anti-inflammatory drugs: current status.
    Mahajan A; Sharma R
    J Assoc Physicians India; 2005 Mar; 53():200-4. PubMed ID: 15926604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Selective COX-2 inhibitors and cardiovascular risk].
    Meier P; Meyer zu Straten A; Burnier M
    Rev Med Suisse; 2005 Feb; 1(8):543-6, 549-50. PubMed ID: 15794303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Problems of cardiovascular toxicity of coxibs and non-selective NSA].
    Forejtová S
    Vnitr Lek; 2006; 52(7-8):677-85. PubMed ID: 16967608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
    Hinz B; Renner B; Brune K
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O; Solomon SD
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
    Harv Heart Lett; 2006 Oct; 17(2):1-3. PubMed ID: 17153752
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular risk and COX-2 inhibition in rheumatological practice.
    Justice E; Carruthers DM
    J Hum Hypertens; 2005 Jan; 19(1):1-5. PubMed ID: 15385947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema?
    Aneja A; Farkouh ME
    Ther Adv Cardiovasc Dis; 2008 Feb; 2(1):53-66. PubMed ID: 19124408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cox-2 inhibitors: still no decisive action.
    Prescrire Int; 2005 Jun; 14(77):102. PubMed ID: 15981408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rheumatology. Do coxibs pose a cardiovascular risk?].
    So A; de Goumoëns P
    Rev Med Suisse; 2005 Jan; 1(2):168-70, 172. PubMed ID: 15773220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can COX-2 inhibitor-induced increase in cardiovascular disease risk be modified by essential fatty acids?
    Das UN
    J Assoc Physicians India; 2005 Jul; 53():623-7. PubMed ID: 16190133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective cyclooxygenase inhibition: its role in pain and anaesthesia.
    Langford RM; Mehta V
    Biomed Pharmacother; 2006 Aug; 60(7):323-8. PubMed ID: 16837162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2 inhibitors and cardiovascular risk.
    Funk CD; FitzGerald GA
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):470-9. PubMed ID: 18030055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 inhibitors--first, do no harm.
    Weatherall M; Aldington S; Shirtcliffe P; Caldwell B; Beasley R
    N Z Med J; 2005 Mar; 118(1211):U1359. PubMed ID: 15778758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.